BRPI0415525A - derivados de imidazola e seu uso como agentes farmacêuticos - Google Patents

derivados de imidazola e seu uso como agentes farmacêuticos

Info

Publication number
BRPI0415525A
BRPI0415525A BRPI0415525-4A BRPI0415525A BRPI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A
Authority
BR
Brazil
Prior art keywords
pharmaceutical agents
imidazole derivatives
cancer
compounds
treatment
Prior art date
Application number
BRPI0415525-4A
Other languages
English (en)
Inventor
Konrad Honold
Stefan Scheiblich
Thomas Von Hirschheydt
Edgar Voss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0415525A publication Critical patent/BRPI0415525A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE IMIDAZOLA E SEU USO COMO AGENTES FARMACêUTICOS". Compostos da fórmula geral (I): são produtos terapêuticos valiosos para o tratamento de câncer e doenças relacionadas ao câncer.
BRPI0415525-4A 2003-10-17 2004-10-15 derivados de imidazola e seu uso como agentes farmacêuticos BRPI0415525A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023677 2003-10-17
PCT/EP2004/011598 WO2005040154A1 (en) 2003-10-17 2004-10-15 Novel imidazole derivatives and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
BRPI0415525A true BRPI0415525A (pt) 2006-12-26

Family

ID=34486074

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415525-4A BRPI0415525A (pt) 2003-10-17 2004-10-15 derivados de imidazola e seu uso como agentes farmacêuticos

Country Status (16)

Country Link
US (1) US7169781B2 (pt)
EP (1) EP1678163B1 (pt)
JP (1) JP2007508344A (pt)
KR (1) KR100796971B1 (pt)
CN (1) CN1867563A (pt)
AR (1) AR046286A1 (pt)
AT (1) ATE420084T1 (pt)
AU (1) AU2004283845A1 (pt)
BR (1) BRPI0415525A (pt)
CA (1) CA2538134A1 (pt)
DE (1) DE602004018962D1 (pt)
ES (1) ES2317030T3 (pt)
MX (1) MXPA06003698A (pt)
RU (1) RU2006116628A (pt)
TW (1) TW200528447A (pt)
WO (1) WO2005040154A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
KR20090007347A (ko) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제
EP2040546A4 (en) * 2006-06-22 2009-12-23 Merck & Co Inc tyrosine kinase inhibitor
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
ATE535520T1 (de) 2006-08-23 2011-12-15 Eisai R&D Man Co Ltd Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
WO2008137619A2 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
DE602008005786D1 (de) 2007-10-03 2011-05-05 Vertex Pharma C-met-proteinkinasehemmer
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
HRP20170317T1 (hr) 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PH12015501130B1 (en) 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
ATE252094T1 (de) 1994-12-13 2003-11-15 Hoffmann La Roche Imidazol derivate mit proteinkinase, insbesondere egf-r tyrosinkinase, inhibierender wirkung
JP2002505690A (ja) * 1997-06-19 2002-02-19 スミスクライン・ビーチャム・コーポレイション 新規なアリールオキシピリミジン置換イミダゾール化合物
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles

Also Published As

Publication number Publication date
CN1867563A (zh) 2006-11-22
WO2005040154A1 (en) 2005-05-06
ES2317030T3 (es) 2009-04-16
JP2007508344A (ja) 2007-04-05
TW200528447A (en) 2005-09-01
AU2004283845A1 (en) 2005-05-06
EP1678163B1 (en) 2009-01-07
KR20060063985A (ko) 2006-06-12
KR100796971B1 (ko) 2008-01-22
US20050113342A1 (en) 2005-05-26
EP1678163A1 (en) 2006-07-12
RU2006116628A (ru) 2007-11-27
CA2538134A1 (en) 2005-05-06
AR046286A1 (es) 2005-11-30
US7169781B2 (en) 2007-01-30
ATE420084T1 (de) 2009-01-15
MXPA06003698A (es) 2006-06-05
DE602004018962D1 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
GB0022438D0 (en) Organic Compounds
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
CY1109728T1 (el) Νεα παραγωγα υδαντοϊνης για τη θεραπεια αποφρακτικων νοσηματων της αναπνευστικης οδου
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
SE0301700D0 (sv) Novel compounds
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
DE50310516D1 (de) Fredericamycin-derivate
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
TW200505452A (en) Chemical compounds
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ECSP066767A (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.